Related Experiment Videos
Experimental models for drug teratogenicity
1Institute of Experimental Medicine, Czechoslovak Academy of Sciences, Praha.
Abstract:
Teratogenicity a specific manifestation of embryotoxicity, is explored in the course of the preclinical phase of drug testing. The official routine rat-rabbit procedures employ an integral experimental model--the whole animal with its species-specific metabolism. Although it has been widely accepted that pharmaco-kinetics of drugs represents the most important source of interspecies differences in teratology, the official procedure is still considered satisfactory. The reason why a new thalidomide affair has not occurred can be explained by the extremely low expression of teratogenic potential at the human population level--a condition inherent in the principles of teratogenesis. On the other hand, many partial experimental models have been developed that use mainly suborganismic objects (i.e. isolated morphogenetic systems, explanted tissues and cell populations). These objects possess many limitations disgracing their use as candidates for replacing the whole-animal experiments. Nevertheless, some of the partial models can be used and must be used in deeper analysis of the teratogenic potential of drugs with the aim of improving the predictive power of embryotoxicity risk assessment. (Fig. 1, Ref. 7.)
Insights
Drug teratogenicity testing uses whole animals, despite pharmacokinetic differences. While partial models have limitations, they can enhance embryotoxicity risk assessment for better drug safety.
Area of Science:
- Pharmacology
- Toxicology
- Developmental Biology
Background:
- Teratogenicity, a form of embryotoxicity, is assessed during preclinical drug testing.
- Current standard methods utilize whole animal models (rats and rabbits) that incorporate species-specific metabolism.
- Pharmacokinetics are recognized as a major factor in interspecies variations in teratology, yet current methods remain satisfactory.
Purpose of the Study:
- To explore the assessment of teratogenicity in preclinical drug development.
- To evaluate the utility and limitations of whole-animal versus partial experimental models in teratogenicity testing.
- To determine how partial models can improve the predictive power of embryotoxicity risk assessment.
Main Methods:
- Review of established rat-rabbit teratogenicity testing procedures.
- Analysis of the role of pharmacokinetics in interspecies differences in teratology.
- Evaluation of various partial experimental models (isolated morphogenetic systems, explanted tissues, cell populations).
Main Results:
- Whole-animal models are the current standard, despite known pharmacokinetic interspecies differences.
- Partial experimental models have significant limitations for replacing whole-animal tests.
- Certain partial models show potential for deeper analysis to improve predictive accuracy.
Conclusions:
- The current whole-animal approach for teratogenicity testing is still considered adequate.
- Partial experimental models, despite limitations, can supplement whole-animal studies for enhanced embryotoxicity risk assessment.
- Integrating specific partial models may improve the prediction of drug-induced developmental toxicity.